September 19th 2024
"But for physicians considering chemotherapy for which there is equipoise, the Decipher test could be used to swing the decision one way or the other," says Gerhardt Attard, MD, PhD, FRCP.
September 16th 2024
Real-world effectiveness and treatment adherence with apalutamide in nmCRPC
October 21st 2021Judd W. Moul, MD discusses data on real-world effectiveness and treatment adherence of apalutamide in non-metastatic castration-resistant prostate cancer patients that was presented at the American Urological Association 2021 Annual Meeting.
Comparing the effectiveness of RALP and ORP
October 6th 2021“I want to reiterate that this study doesn't necessarily say that 1 approach is better than the other, but it definitely does reinforce some advantages of robotic surgery that have been shown not just in this study, but in other studies as well,” says Peter Chang, MD, PhD.
Examining financial factors in prostate cancer treatment patterns
October 1st 2021“I think the key [is to not] get rid of financial incentives. I don't think that's possible. [Rather, we should] align financial incentives [so] that [we] can promote what is best for patients,” says Lillian Y. Lai, MD.
Prostate cancer and CV risk: The heart of the matter
September 28th 2021"Perhaps there is another Nobel Prize waiting to be had if we could reduce the cardiovascular effect of ADT and unlock the answer to the controversy surrounding the comparative safety and impact on cardiovascular health between GnRH agonists and antagonists," writes Michael S. Cookson, MD, MMHC.
Interest grows for focal therapy in treating prostate cancer
September 28th 2021In this interview, Ardeshir (Art) Rastinehad, DO, discusses the current state of focal therapy in prostate cancer, the role of fusion biopsy in pushing the treatment forward, and what institutions looking to implement focal therapy should know.
Study finds commercial prices for prostatectomies are not associated with treatment patterns
September 27th 2021"What will probably be surprising to the reader is that patients managed in markets with higher average prices for prostatectomy were not more likely to undergo treatment," says Lillian Y. Lai, MD.
Transperineal biopsy technology offers more efficient prostate cancer detection
September 8th 2021In this interview, urologist Matthew J. Allaway, MD, gives an overview of transrectal vs transperineal biopsies, discusses how his own cancer battle influenced his professional path, and how his PrecisionPoint system aids in the detection of prostate cancer.
2021 AUA Annual Meeting Preview: Prostate, Bladder, and Kidney Cancer
September 8th 2021Michael S. Cookson, MD, previews the 2021 AUA Annual Meeting, with a focus on prostate, bladder, and kidney cancer. His in-depth analysis covers the plenary sessions, late-breaking abstracts, and other abstracts of interest.
Emerging treatment options for the management of metastatic castration-resistant prostate cancer
September 7th 2021“When a man initially presents with metastatic disease, or fails initial systemic therapy, our approach has to be different. We are more concerned that their disease is more aggressive,” says Leonard Gomella, MD.
Transperineal biopsy device PrecisionPoint shows promise
September 7th 2021“Through these 2 small punctures, we can manipulate the device with the methodology to sample the entire prostate, both anterior apical and the posterior regions, where we find the vast majority of our cancers,” says Matthew A. Allaway, MD.
Advantages of transperineal biopsies over transrectal biopsies
September 5th 2021“The transperineal [prostate biopsy] approach is safer because the needles are passed through the perineal skin…so, we can sterilize that skin and if we enter through that passageway, we mitigate, if not eliminate, the risk of infection and sepsis,” says Matthew J. Allaway, MD.